6 mg or 12 mg once per day, tofacitinib (Xeljanz, Pfizer) 5 mg twice per day and upadacitinib (Rinvoq, Abbvie) 15 mg daily. The meta-analysis ultimately included nine randomized controlled trials ...

Xeljanz (tofacitinib) is approved at the higher dose of 10 mg twice daily in patients with ulcerative colitis, although this can be reduced to 5 mg twice daily in patients who respond well.

The FDA has concluded its safety review of Pfizer's JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings for the drugs as well as others in the class after finding evidence of elevated ...

Among participants in the landmark ORAL Surveillance study assigned to the JAK inhibitor tofacitinib (Xeljanz ... lower when the tofacitinib dose was 5 mg twice daily (HR 0.84, 95% CI 0.34-2. ...